ARTICLE | Clinical News
BIBR277HCT regulatory update
February 12, 2007 8:00 AM UTC
Astellas filed an NDA in Japan for BIBR277HCT to treat hypertension. The product is a combination of a diuretic and telmisartan, an angiotensin II receptor (type AT1) blocker. Telmisartan is marketed...